Longitudinal associations between smoking and affect among cancer patients using varenicline to quit smoking. (August 2019)

• Record Type: Journal Article
• Authors: Carroll, Allison J.; Kim, Kristine; Miele, Andrew; Olonoff, Matthew; Leone, Frank T.; Schnoll, Robert A.; Hitsman, Brian
• Is Part Of: Addictive behaviors. Volume 95(2019)
• Page Start: 206
• Page End: 210
• Publication Date: 2019-08
• Subjects: Smoking cessation -- Affect -- Adherence -- Cancer -- Randomized controlled trial; Substance abuse -- Periodicals; Alcoholism -- Periodicals; Drug addiction -- Periodicals; Nicotine addiction -- Periodicals; Smoking -- Periodicals; Gambling -- Psychological aspects -- Periodicals; Electronic journals; 362.29
• DOI: 10.1016/j.addbeh.2019.04.003
• Languages: English
• ISSNs: 0306-4603

Abstract

Abstract: During a quit attempt, high negative affect predicts relapse to smoking. In this study, we evaluated bidirectional longitudinal associations between smoking and negative affect among cancer patients treated with varenicline. Participants ( N = 119, 50% female, Mage = 59 years) were smokers (≥5 cigarettes/week) who were diagnosed with cancer and were recruited for a 24-week trial of extended duration varenicline plus behavioral counseling; data for this secondary analyses were drawn from the 12-week open-label phase of the trial. Smoking was assessed via self-reported number of cigarettes in the past 24 h. Negative affect was assessed using the Positive and Negative Affect Scale (PANAS). Data were collected at pre-quit (week 0), target quit day (week 1), week 4, and week 12. We evaluated cross-lagged panel models for negative affect and smoking using PROC CALIS in SAS. Models were run separately for participants who were adherent (≥80% of medication taken) or nonadherent to varenicline. Among adherent participants ( n = 96), smoking accounted for up to 22% of variance in subsequent negative affect throughout treatment. Cross-lagged associations were not observed between smoking and negative affect among non-adherent participants ( n = 23). Negative affect did not predict subsequent smoking among either adherent or nonadherent participants. These results suggest that varenicline may attenuate abstinence-induced negative affect among cancer patients treated for nicotine dependence. Highlights: Negative affect during a quit attempt predicted subsequent smoking. Smoking did not predict later negative affect among cancer patients trying to quit. Varenicline attenuated abstinence-induced negative affect among cancer patients.